Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online January 13, 2005.
Copyright & Usage
THE JOURNAL OF NUCLEAR MEDICINE
Author Information
- Roelf Valkema, MD1,
- Stanislas A. Pauwels, MD2,
- Larry K. Kvols, MD3,
- Dik J. Kwekkeboom, MD1,
- Francois Jamar, MD2,
- Marion de Jong, PhD1,
- Raffaella Barone, MD2,
- Stephan Walrand, PhD2,
- Peter P.M. Kooij, MSc1,
- Willem H. Bakker, PhD1,
- Janet Lasher4 and
- Eric P. Krenning, MD1
- 1Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
- 2Service de Medecine Nucleaire, Cliniques Universitaires Saint-Luc, Universite Catholique Louvain, Brussels, Belgium
- 3Gastrointestinal Tumor Program, H. Lee Moffitt Cancer Hospital, University of South Florida, Tampa, Florida
- 4Novartis Pharmaceuticals Corp., East Hanover, New Jersey
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy
- Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
- The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study
- Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung
- Recombinant {alpha}1-Microglobulin Is a Potential Kidney Protector in 177Lu-Octreotate Treatment of Neuroendocrine Tumors
- Proof of Therapeutic Efficacy of a 177Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model
- 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function
- Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting
- MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy
- GEP-NETS UPDATE: Radionuclide therapy in neuroendocrine tumors
- Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
- 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- In Vitro Evaluation of Targeted Antisense 177Lu Radiotherapy
- Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
- 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors
- MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response--Implications for Radionuclide Therapy
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors
- Gastrointestinal neuroendocrine tumors: a role for targeted therapies?
- Radiation Dose Distribution in Human Kidneys by Octreotides in Peptide Receptor Radionuclide Therapy
- Dosimetry in Peptide Radionuclide Receptor Therapy: A Review
- Renal Uptake of Radiolabeled Octreotide in Human Subjects Is Efficiently Inhibited by Succinylated Gelatin
- Gelatin-Based Plasma Expander Effectively Reduces Renal Uptake of 111In-Octreotide in Mice and Rats
- Oral Versus Intravenous Administration of Lysine: Equal Effectiveness in Reduction of Renal Uptake of [111In-DTPA]Octreotide
- Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
- Patient-Specific Dosimetry in Predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose-Effect Relationship